JP4617300B2 - インフルエンザワクチン組成物を生成する方法 - Google Patents
インフルエンザワクチン組成物を生成する方法 Download PDFInfo
- Publication number
- JP4617300B2 JP4617300B2 JP2006508841A JP2006508841A JP4617300B2 JP 4617300 B2 JP4617300 B2 JP 4617300B2 JP 2006508841 A JP2006508841 A JP 2006508841A JP 2006508841 A JP2006508841 A JP 2006508841A JP 4617300 B2 JP4617300 B2 JP 4617300B2
- Authority
- JP
- Japan
- Prior art keywords
- influenza virus
- virus
- influenza
- tcid
- titer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims description 186
- 238000000034 method Methods 0.000 title claims description 163
- 229960003971 influenza vaccine Drugs 0.000 title description 14
- 241000712461 unidentified influenza virus Species 0.000 claims description 154
- 235000013601 eggs Nutrition 0.000 claims description 137
- 238000001914 filtration Methods 0.000 claims description 75
- 108090000623 proteins and genes Proteins 0.000 claims description 56
- 238000010792 warming Methods 0.000 claims description 32
- 229930006000 Sucrose Natural products 0.000 claims description 30
- 239000005720 sucrose Substances 0.000 claims description 30
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 29
- 229920000159 gelatin Polymers 0.000 claims description 27
- 235000019322 gelatine Nutrition 0.000 claims description 27
- 239000004475 Arginine Substances 0.000 claims description 26
- 108010010803 Gelatin Proteins 0.000 claims description 26
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 26
- 239000008273 gelatin Substances 0.000 claims description 26
- 235000011852 gelatine desserts Nutrition 0.000 claims description 26
- 238000011534 incubation Methods 0.000 claims description 25
- 230000002238 attenuated effect Effects 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 20
- 239000012530 fluid Substances 0.000 claims description 19
- 238000010438 heat treatment Methods 0.000 claims description 16
- 208000037798 influenza B Diseases 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 13
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 12
- 239000012528 membrane Substances 0.000 claims description 9
- 230000029812 viral genome replication Effects 0.000 claims description 8
- 241000712431 Influenza A virus Species 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 230000008093 supporting effect Effects 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 2
- 239000008057 potassium phosphate buffer Substances 0.000 claims 4
- 238000001816 cooling Methods 0.000 claims 2
- 241000700605 Viruses Species 0.000 description 321
- 238000003556 assay Methods 0.000 description 157
- 210000004027 cell Anatomy 0.000 description 124
- 229960005486 vaccine Drugs 0.000 description 105
- 230000000120 cytopathologic effect Effects 0.000 description 80
- 238000004519 manufacturing process Methods 0.000 description 76
- 238000009472 formulation Methods 0.000 description 70
- 238000012360 testing method Methods 0.000 description 59
- 239000000243 solution Substances 0.000 description 56
- 238000002835 absorbance Methods 0.000 description 45
- 206010022000 influenza Diseases 0.000 description 43
- 230000003612 virological effect Effects 0.000 description 43
- 238000004113 cell culture Methods 0.000 description 42
- 239000000523 sample Substances 0.000 description 41
- 238000005406 washing Methods 0.000 description 34
- 239000000975 dye Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 29
- 238000010790 dilution Methods 0.000 description 28
- 239000012895 dilution Substances 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 27
- 208000015181 infectious disease Diseases 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 238000011109 contamination Methods 0.000 description 26
- 238000001514 detection method Methods 0.000 description 25
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 23
- 239000000047 product Substances 0.000 description 23
- 239000002245 particle Substances 0.000 description 22
- 238000011053 TCID50 method Methods 0.000 description 21
- 239000012535 impurity Substances 0.000 description 21
- 229940124895 FluMist Drugs 0.000 description 19
- 108010058846 Ovalbumin Proteins 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 102000005348 Neuraminidase Human genes 0.000 description 17
- 108010006232 Neuraminidase Proteins 0.000 description 17
- 229940092253 ovalbumin Drugs 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 238000013207 serial dilution Methods 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 241000287828 Gallus gallus Species 0.000 description 16
- 230000012010 growth Effects 0.000 description 16
- 238000010367 cloning Methods 0.000 description 15
- 208000037797 influenza A Diseases 0.000 description 15
- 230000000813 microbial effect Effects 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 239000000463 material Substances 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000012466 permeate Substances 0.000 description 14
- 238000004007 reversed phase HPLC Methods 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 13
- 101710154606 Hemagglutinin Proteins 0.000 description 12
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 12
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 12
- 101710176177 Protein A56 Proteins 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 239000000185 hemagglutinin Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 230000000717 retained effect Effects 0.000 description 11
- 241000713196 Influenza B virus Species 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 10
- 239000005723 virus inoculator Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 239000013553 cell monolayer Substances 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 210000003501 vero cell Anatomy 0.000 description 9
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 230000006641 stabilisation Effects 0.000 description 8
- 238000011105 stabilization Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 7
- 102000016943 Muramidase Human genes 0.000 description 7
- 108010014251 Muramidase Proteins 0.000 description 7
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 7
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 description 7
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 description 7
- 208000021267 infertility disease Diseases 0.000 description 7
- 229960000274 lysozyme Drugs 0.000 description 7
- 235000010335 lysozyme Nutrition 0.000 description 7
- 239000004325 lysozyme Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 239000002356 single layer Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000003322 Coinfection Diseases 0.000 description 6
- 108010000912 Egg Proteins Proteins 0.000 description 6
- 102000002322 Egg Proteins Human genes 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 108010026206 Conalbumin Proteins 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229940124873 Influenza virus vaccine Drugs 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 241000755649 Midgee Species 0.000 description 5
- 108010064983 Ovomucin Proteins 0.000 description 5
- 241000845082 Panama Species 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 229940124590 live attenuated vaccine Drugs 0.000 description 5
- 229940023012 live-attenuated vaccine Drugs 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 5
- 235000013923 monosodium glutamate Nutrition 0.000 description 5
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 5
- 229910000160 potassium phosphate Inorganic materials 0.000 description 5
- 235000011009 potassium phosphates Nutrition 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- 241000271566 Aves Species 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 102400001232 IL-8(6-77) Human genes 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- 102000011931 Nucleoproteins Human genes 0.000 description 4
- 108010061100 Nucleoproteins Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 108091034135 Vault RNA Proteins 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012468 concentrated sample Substances 0.000 description 4
- 238000009295 crossflow filtration Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000008092 positive effect Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000001931 thermography Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000204031 Mycoplasma Species 0.000 description 3
- 241000831652 Salinivibrio sharmensis Species 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- -1 for example Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000004264 monolayer culture Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000011045 prefiltration Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 210000000605 viral structure Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 101150044182 8 gene Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 101150039660 HA gene Proteins 0.000 description 2
- 241000282339 Mustela Species 0.000 description 2
- 101150080862 NA gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013103 analytical ultracentrifugation Methods 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 231100000409 cytocidal Toxicity 0.000 description 2
- 230000000445 cytocidal effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000010460 detection of virus Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 230000009643 growth defect Effects 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 229960001226 live attenuated influenza Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000004223 monosodium glutamate Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012429 release testing Methods 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108020005097 23S Ribosomal RNA Proteins 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 201000003695 Alexia Diseases 0.000 description 1
- 241000752021 Alexia Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006585 Bunion Diseases 0.000 description 1
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 101100028758 Influenza A virus (strain A/Swine/Wisconsin/1/1967 H1N1) PB1-F2 gene Proteins 0.000 description 1
- 241000713174 Influenza B virus (B/Ann Arbor/1/1966 [wild- type]) Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 101150109178 M1 gene Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 241001508003 Mycobacterium abscessus Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 241000202942 Mycoplasma synoviae Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 101150103639 PB1 gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 208000012642 Sexual Trauma Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 208000015707 frontal fibrosing alopecia Diseases 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000012569 microbial contaminant Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000013180 random effects model Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/147—Microfiltration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Water Supply & Treatment (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45018103P | 2003-02-25 | 2003-02-25 | |
| PCT/US2004/005697 WO2005014862A1 (en) | 2003-02-25 | 2004-02-25 | Methods of producing inflenza vaccine compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006519028A JP2006519028A (ja) | 2006-08-24 |
| JP2006519028A5 JP2006519028A5 (https=) | 2007-04-12 |
| JP4617300B2 true JP4617300B2 (ja) | 2011-01-19 |
Family
ID=34135009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006508841A Expired - Fee Related JP4617300B2 (ja) | 2003-02-25 | 2004-02-25 | インフルエンザワクチン組成物を生成する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US7262045B2 (https=) |
| EP (2) | EP1597400B8 (https=) |
| JP (1) | JP4617300B2 (https=) |
| KR (4) | KR101190932B1 (https=) |
| CN (2) | CN100582244C (https=) |
| AU (2) | AU2004263813B8 (https=) |
| CA (2) | CA2807534A1 (https=) |
| WO (1) | WO2005014862A1 (https=) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7465456B2 (en) | 2002-04-26 | 2008-12-16 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
| ES2526191T3 (es) | 2002-04-26 | 2015-01-08 | Medimmune, Llc | Método para producir virus influenza B infeccioso en cultivo celular |
| CN1788089A (zh) * | 2002-07-03 | 2006-06-14 | 巴斯福股份公司 | 用于提高泛酸产量的微生物和方法 |
| US7262045B2 (en) | 2003-02-25 | 2007-08-28 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
| US20060110406A1 (en) | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| US7566458B2 (en) | 2003-06-16 | 2009-07-28 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| ATE469972T1 (de) | 2003-12-23 | 2010-06-15 | Medimmune Llc | Multiplasmid-system zur erzeugung des grippevirus |
| EP2821135A1 (en) * | 2004-02-05 | 2015-01-07 | EMD Millipore Corporation | Porous adsorptive or chromatographic media |
| JP5147405B2 (ja) * | 2004-10-06 | 2013-02-20 | メディミューン，エルエルシー | 冷蔵温度安定型インフルエンザワクチン組成物 |
| ES2536745T3 (es) | 2004-12-08 | 2015-05-28 | Medimmune, Llc | Métodos de producción de composiciones de vacuna contra la gripe |
| ATE547511T1 (de) | 2004-12-23 | 2012-03-15 | Medimmune Llc | Nichttumorbildende mdck-zellinie zur vermehrung von viren |
| EP2441471B1 (en) | 2005-03-08 | 2014-10-08 | MedImmune, LLC | Reassortant influenza viruses |
| EP3088893B1 (en) * | 2005-04-13 | 2018-02-14 | Merial, Inc. | Assay for monitoring porcine circovirus production |
| CN101189030A (zh) * | 2005-06-02 | 2008-05-28 | 阿尔扎公司 | 透皮递送器械的最终消毒方法 |
| US7790434B2 (en) * | 2005-06-21 | 2010-09-07 | Medimmune, Llc | Methods and compositions for expressing negative-sense viral RNA in canine cells |
| RU2008101367A (ru) | 2005-06-21 | 2009-08-10 | Медиммун, Ллк (Us) | Способы и композиции для экспрессии отрицательной смысловой вирусной рнк в собачьих клетках |
| WO2007019232A2 (en) | 2005-08-03 | 2007-02-15 | Immunogen, Inc. | Immunoconjugate formulations |
| GB0613977D0 (en) * | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
| US7534596B2 (en) * | 2006-02-10 | 2009-05-19 | Solohill Engineering, Inc. | Method and device for producing vaccine |
| PT2016194E (pt) | 2006-04-19 | 2015-07-20 | Medimmune Llc | Métodos e composições para expressar arn viral de polaridade negativa em células caninas |
| GB0614460D0 (en) * | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| WO2008105931A2 (en) | 2006-09-15 | 2008-09-04 | Medimmune Vaccines, Inc. | Mdck cell lines supporting viral growth to high titers and bioreactor process using the same |
| KR20090088944A (ko) * | 2006-12-15 | 2009-08-20 | 쉐링-프라우 리미티드 | 배양물 속에서 인플루엔자 바이러스를 복제하는 방법 |
| AR065640A1 (es) * | 2007-03-09 | 2009-06-17 | Otsuka Pharma Co Ltd | Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma |
| CA2690196A1 (en) | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Influenza b viruses having alterations in the hemaglutinin polypeptide |
| US9433922B2 (en) * | 2007-08-14 | 2016-09-06 | Emd Millipore Corporation | Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same |
| EP2217064A4 (en) * | 2007-11-12 | 2012-10-03 | Univ Pennsylvania | NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES |
| US20090130738A1 (en) * | 2007-11-19 | 2009-05-21 | Mikhail Kozlov | Media for membrane ion exchange chromatography |
| EP2072058A1 (en) * | 2007-12-21 | 2009-06-24 | Avir Green Hills Biotechnology Research Development Trade Ag | Modified influenza virus |
| JP2011184299A (ja) * | 2008-07-02 | 2011-09-22 | Asahi Kasei Medical Co Ltd | モノクローナル抗体を含む製剤の製造方法 |
| CN102215865B (zh) | 2008-09-24 | 2013-10-30 | 米迪缪尼有限公司 | 病毒纯化方法 |
| RU2547587C2 (ru) | 2008-09-24 | 2015-04-10 | Медиммун, Ллк | Способы культивирования клеток, размножения и очистки вирусов |
| US8815252B2 (en) * | 2008-11-25 | 2014-08-26 | Baxter Healthcare Sa | Method for production of pH stable enveloped viruses |
| JP5686741B2 (ja) | 2008-12-16 | 2015-03-18 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | インフルエンザワクチンの生成 |
| CN101450209B (zh) * | 2008-12-31 | 2012-01-25 | 中国人民解放军军事医学科学院微生物流行病研究所 | 透皮免疫流感多价疫苗的制备及其方法 |
| RU2424762C2 (ru) * | 2009-05-06 | 2011-07-27 | Валерий Денисович Белокрылов | Способ и автоматизированное устройство (два варианта) для диагностики заболеваний, вызванных вирусом a/h1n1 и его мутациями |
| WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
| US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| AU2010270722B2 (en) | 2009-07-06 | 2015-06-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| US20120077249A1 (en) * | 2010-04-20 | 2012-03-29 | Millipore Corporation | Separation Of Virus And/Or Protein From Nucleic Acids By Primary Amines |
| MX342138B (es) | 2010-07-06 | 2016-09-14 | Variation Biotechnologies Inc | Composiciones y metodos para el tratamiento de influenza. |
| US8606750B2 (en) * | 2010-11-12 | 2013-12-10 | Life Technologies Corporation | Systems and methods for laboratory assay validation or verification |
| CA2862871C (en) | 2011-01-13 | 2020-09-22 | Variation Biotechnologies Inc. | Methods for preparing vesicles and formulations produced therefrom |
| CA2862864C (en) | 2011-01-13 | 2018-12-11 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| EP2694645A1 (en) | 2011-04-08 | 2014-02-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for increasing the replication capacity of an influenza virus in cultured cells |
| EP2710381A2 (en) | 2011-05-16 | 2014-03-26 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for screening substances capable of modulating the replication of an influenza virus |
| CA2841604C (en) * | 2011-07-20 | 2020-01-21 | Abbott Biologicals B.V. | Process for producing viral antigen and vaccines |
| US20140328876A1 (en) | 2011-11-18 | 2014-11-06 | Variation Biotechnologies Inc. | Synthetic derivatives of mpl and uses thereof |
| WO2013092985A1 (en) * | 2011-12-23 | 2013-06-27 | Novartis Ag | Stable compositions for immunising against staphylococcus aureus |
| US20140356399A1 (en) | 2012-01-12 | 2014-12-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
| US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
| US20130309700A1 (en) * | 2012-05-21 | 2013-11-21 | Celsis International Limited | Methods, devices, and systems of detecting microorganisms |
| US9932620B2 (en) | 2012-05-21 | 2018-04-03 | Celsis Ltd. | Methods, devices, and systems of detecting microorganisms |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| KR20140112255A (ko) | 2013-03-13 | 2014-09-23 | 고려대학교 산학협력단 | 바이러스 생산능이 증가된 세포주 및 그 제조방법 |
| EP2975119B1 (en) | 2013-03-13 | 2020-03-11 | ImmunoMax Co., Ltd. | Cell strain having increased virus production ability and production method therefor |
| US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
| US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
| WO2015017673A1 (en) * | 2013-08-01 | 2015-02-05 | Medimmune, Llc | Methods for producing influenza vaccine compositions |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| US9579374B2 (en) | 2013-12-04 | 2017-02-28 | The Johns Hopkins University | Method for rapidly designing pharmaceutical preparations for preventing viral infection |
| AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
| TWI670085B (zh) * | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
| WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
| US10426828B2 (en) * | 2014-04-03 | 2019-10-01 | Biondvax Pharmaceuticals Ltd. | Compositions of multimeric-multiepitope influenza polypeptides and their production |
| JP6708636B2 (ja) | 2014-06-18 | 2020-06-10 | イミュノマックス カンパニー リミテッドＩｍｍｕｎｏｍａｘ Ｃｏ．， Ｌｔｄ． | Ｂｓｔ２遺伝子の機能が喪失された細胞株を利用したウィルス感染促進及び産生増進方法 |
| AU2015357225B2 (en) | 2014-12-01 | 2020-04-09 | Transgene Sa | Stable liquid vaccinia virus formulations |
| ES3011733T3 (en) | 2015-02-13 | 2025-04-08 | Transgene | Immunotherapeutic vaccine and antibody combination therapy |
| CN104984357B (zh) * | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | 不含明胶的疫苗保护剂组合物及流感减毒活疫苗 |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| WO2017090769A1 (ja) * | 2015-11-27 | 2017-06-01 | 日東電工株式会社 | インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法 |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| JP7034949B2 (ja) | 2016-05-25 | 2022-03-14 | テルモ ビーシーティー、インコーポレーテッド | 細胞の増殖 |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| CN117247899A (zh) | 2017-03-31 | 2023-12-19 | 泰尔茂比司特公司 | 细胞扩增 |
| CN110603058A (zh) | 2017-05-15 | 2019-12-20 | 扬森疫苗与预防公司 | 含有病毒的稳定组合物 |
| KR102658198B1 (ko) | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정한 바이러스 함유 조성물 |
| JP2021516957A (ja) | 2018-03-07 | 2021-07-15 | トランジェーヌＴｒａｎｓｇｅｎｅ | パラポックスウイルスベクター |
| JP7625521B2 (ja) | 2018-12-28 | 2025-02-03 | トランスジーン | ｍ２欠陥ポックスウイルス |
| WO2020136232A1 (en) | 2018-12-28 | 2020-07-02 | Transgene Sa | Immunosuppressive m2 protein |
| JP7660514B2 (ja) * | 2019-02-15 | 2025-04-11 | セラム インスティチュート オブ インディア プライベイト リミテッド | 弱毒生インフルエンザワクチン組成物及びその調製プロセス |
| US20230114464A1 (en) * | 2020-03-12 | 2023-04-13 | Bavarian Nordic A/S | Conditions Improving Poxvirus Stability |
| WO2022148736A1 (en) | 2021-01-05 | 2022-07-14 | Transgene | Vectorization of muc1 t cell engager |
| KR20260001978A (ko) | 2024-06-28 | 2026-01-06 | 주식회사 엔에프방재 | 화재 방재용 방패 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB660109A (en) * | 1946-10-01 | 1951-10-31 | American Cyanamid Co | Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine |
| US4158054A (en) * | 1973-10-18 | 1979-06-12 | Duncan Flockhart & Co. Ltd. | Preparation of virus sub-unit vaccines |
| US3874999A (en) * | 1973-10-31 | 1975-04-01 | American Cyanamid Co | Process for the purification of virus vaccine |
| US4000257A (en) * | 1975-12-22 | 1976-12-28 | American Cyanamid Company | Process for the purification of influenza virus vaccine |
| US4057626A (en) | 1976-10-08 | 1977-11-08 | Richardson-Merrell Inc. | Process for detoxifying influenza B virus |
| US4338296A (en) * | 1979-10-16 | 1982-07-06 | Smithkline-Rit | Influenza virus and process of producing a vaccine therefrom |
| JPS57114527A (en) * | 1979-10-29 | 1982-07-16 | Merck & Co Inc | Vaccine stabilizer |
| US4338335A (en) * | 1980-02-05 | 1982-07-06 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| US4337242A (en) * | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| US4512972A (en) * | 1980-06-30 | 1985-04-23 | Kureha Chemical Industry Co., Ltd. | Nasal preparation and processes for their production |
| FR2505657A1 (fr) | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| US4512285A (en) * | 1983-12-27 | 1985-04-23 | Gof Manufacturing Company, Inc. | Apparatus and method for egg turning during incubation |
| GB8914968D0 (en) | 1989-06-29 | 1989-08-23 | Connaught Lab | Production of virus and purification of viral envelope proteins for vaccine use |
| CA2065023A1 (en) * | 1989-08-15 | 1991-02-16 | Brent Dorval | Stabilized vaccine compositions |
| CA2075521C (en) | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Stabilized live vaccine |
| US7344722B1 (en) * | 1993-06-29 | 2008-03-18 | The Regents Of The University Of Michigan | Cold-adapted influenza virus |
| US5824536A (en) | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
| US6146873A (en) | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
| EP0865296B1 (en) | 1995-10-20 | 2002-02-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Influenza vaccine |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6177082B1 (en) * | 1998-08-13 | 2001-01-23 | The University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Cold-adapted equine influenza viruses |
| CA2355270A1 (en) | 1998-12-17 | 2000-06-22 | Aventis Pasteur Limited | Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| IL149459A0 (en) * | 1999-11-12 | 2002-11-10 | Fibrogen Inc | Recombinant gelatins |
| CN1147316C (zh) * | 2000-03-16 | 2004-04-28 | 辽宁天成生物制药研究所 | 流感病毒静水压技术灭活工艺制备疫苗的方法 |
| MXPA02010642A (es) | 2000-04-28 | 2004-05-17 | St Jude Children S Res Hospital | Sistema de transfeccion de adn para la generacion de virus de influenza infeccioso. |
| BRPI0002694C1 (pt) | 2000-06-19 | 2021-05-25 | Fund Butantan | processo de obtenção de vacina contra raiva em células vero, para uso humano |
| US7494659B2 (en) | 2000-09-25 | 2009-02-24 | Polymun Scientific Immunbiologische Forschung Gmbh | Live attenuated influenza vaccine |
| ATE503493T1 (de) | 2001-02-23 | 2011-04-15 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| WO2004030608A2 (en) * | 2001-06-05 | 2004-04-15 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| US7195905B2 (en) | 2001-12-10 | 2007-03-27 | Baxter Healthcare S.A. | Enveloped virus vaccine and method for production |
| US7135180B2 (en) * | 2002-04-11 | 2006-11-14 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| CA2484052C (en) * | 2002-04-11 | 2011-06-14 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by spray drying |
| ES2526191T3 (es) | 2002-04-26 | 2015-01-08 | Medimmune, Llc | Método para producir virus influenza B infeccioso en cultivo celular |
| KR20050088175A (ko) | 2002-12-17 | 2005-09-02 | 메드이뮨 백신즈 인코포레이티드 | 생물활성 물질의 고압 분무 건조 |
| US7262045B2 (en) | 2003-02-25 | 2007-08-28 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
| US20060110406A1 (en) | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| ATE469972T1 (de) | 2003-12-23 | 2010-06-15 | Medimmune Llc | Multiplasmid-system zur erzeugung des grippevirus |
| EP2995678A1 (en) | 2004-05-24 | 2016-03-16 | MedImmune, LLC | Multi plasmid system for the production of attenuated influenza b virus |
| JP5147405B2 (ja) | 2004-10-06 | 2013-02-20 | メディミューン，エルエルシー | 冷蔵温度安定型インフルエンザワクチン組成物 |
-
2004
- 2004-02-25 US US10/788,236 patent/US7262045B2/en not_active Expired - Lifetime
- 2004-02-25 KR KR1020057015867A patent/KR101190932B1/ko not_active Expired - Fee Related
- 2004-02-25 KR KR1020137013536A patent/KR101357443B1/ko not_active Expired - Lifetime
- 2004-02-25 CN CN200480011005A patent/CN100582244C/zh not_active Expired - Fee Related
- 2004-02-25 JP JP2006508841A patent/JP4617300B2/ja not_active Expired - Fee Related
- 2004-02-25 EP EP04775805.7A patent/EP1597400B8/en not_active Expired - Lifetime
- 2004-02-25 CN CN200910266807.9A patent/CN101804202B/zh not_active Expired - Lifetime
- 2004-02-25 CA CA2807534A patent/CA2807534A1/en not_active Abandoned
- 2004-02-25 CA CA2517181A patent/CA2517181C/en not_active Expired - Fee Related
- 2004-02-25 AU AU2004263813A patent/AU2004263813B8/en not_active Ceased
- 2004-02-25 KR KR1020127020501A patent/KR101360300B1/ko not_active Expired - Lifetime
- 2004-02-25 KR KR1020127005217A patent/KR101251902B1/ko not_active Expired - Lifetime
- 2004-02-25 WO PCT/US2004/005697 patent/WO2005014862A1/en not_active Ceased
- 2004-02-25 EP EP12155639A patent/EP2481819A1/en not_active Ceased
-
2007
- 2007-01-30 US US11/668,587 patent/US20070161085A1/en not_active Abandoned
-
2008
- 2008-10-21 AU AU2008230033A patent/AU2008230033B2/en not_active Expired
- 2008-12-08 US US12/330,299 patent/US20090246225A1/en not_active Abandoned
-
2013
- 2013-02-27 US US13/779,668 patent/US8986705B2/en not_active Expired - Lifetime
-
2015
- 2015-03-04 US US14/638,909 patent/US20160051660A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4617300B2 (ja) | インフルエンザワクチン組成物を生成する方法 | |
| US8012737B2 (en) | Methods of producing influenza vaccine compositions | |
| KR101376889B1 (ko) | 냉장 온도 안정성 인플루엔자 백신 조성물 | |
| AU2012201973B2 (en) | Methods of producing influenza vaccine compositions | |
| HK1174066A (en) | Cross flow filtration in the production of stabilized influenza vaccine compositions | |
| HK1077085B (en) | Methods of producing influenza vaccine compositions | |
| AU2014210661A1 (en) | Methods of producing influenza vaccine compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070220 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100105 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100317 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100325 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20100524 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100705 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100907 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100924 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100929 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101025 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131029 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |